川崎病

McCrindle BW, Rowley AH, Newburger JW, et al; American Heart Association. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the American Heart Association. Circulation. 2017;135:e927-e999.

• 全文
• 摘要

Kawasaki T, Kosaki T, Okawa S, et al. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974;54:271-276.

• 摘要

Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324:1633-1639.

• 摘要

Han RK, Sinclair B, Newman A, et al. Recognition and management of Kawasaki disease. CMAJ. 2000;162:807-812.

• 全文
• 摘要

Newberger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 2007;356:663-675.

• 全文
• 摘要

Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005;146:662-667.

• 摘要

1.  McCrindle BW, Rowley AH, Newburger JW, et al; American Heart Association. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the American Heart Association. Circulation. 2017;135:e927-e999.

• 全文
• 摘要

2.  Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children [in Japanese]. Arerugi. 1967;16:178-222.

• 摘要

3.  Mason WH, Takahashi M. Kawasaki syndrome. Clin Infect Dis. 1999;28:169-185.

• 摘要

4.  Callinan LS, Holman RC, Vugia DJ, et al. Kawasaki disease hospitalization rate among children younger than 5 years of age in California, 2003-2010. Pediatr Infect Dis J. 2014;33:781-783.

• 摘要

5.  Holman RC, Curns AT, Belay ED, et al. Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. Pediatrics. 2003;112:495-501.

• 摘要

6.  Holman RC, Belay ED, Clarke MJ, et al. Kawasaki syndrome among American Indian and Alaska native children. Pediatr Infect Dis J. 1999;18:451-455.

• 摘要

7.  Yanagawa H, Nakamura Y, Ojima T, et al. Changes in epidemic patterns of Kawasaki disease in Japan. Pediatr Infect Dis J. 1999;18:64-66.

• 摘要

8.  Yanagawa H, Yashiro M, Nakamura Y, et al. Nationwide surveillance of Kawasaki disease in Japan, 1984 to 1993. Pediatr Infect Dis J. 1995;14:69-71.

• 摘要

9.  Dominguez SR, Anderson MS, Glode MP, et al. Blinded case-control study of the relationship between human coronavirus NL63 and Kawasaki syndrome. J Infect Dis. 2006;194:1635-1637.

• 摘要

10.  Abinun M, Cant AJ. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet. 1994;343:300.

• 摘要

11.  Meissner HC, Leung DY. Superantigens, conventional antigens and etiology of Kawasaki syndrome. Pediatr Infect Dis J. 2000;19:91-94.

• 摘要

12.  Leung DY, Meissner HC, Fulton DR, et al. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet. 1993;342:1385-1388.

• 摘要

13.  Rowley AH. Kawasaki disease: novel insights into etiology and genetic susceptibility. Annu Rev Med. 2011;62:69-77.

• 摘要

14.  Hata A, Onouchi Y. Susceptibility genes for Kawasaki disease: toward implementation of personalized medicine. J Hum Genet. 2009;54:67-73.

• 摘要

15.  Khor CC, Davila S, Breunis WB, et al. Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat Genet. 2011;43:1241-1246.

• 摘要

16.  Rowley AH, Shulman ST. New developments in the search for etiologic agent of Kawasaki disease. Curr Opin Pediatr. 2007;19:71-74.

• 摘要

17.  Dajani AS, Taubert KA, Gerber MA, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation. 1993;87:1776-1780.

• 摘要

18.  Takahashi K, Oharaseki T, Naoe S, et al. Neutrophilic involvement in the damage to coronary arteries in acute stage of Kawasaki disease. Pediatr Int. 2005;47:305-310.

• 摘要

19.  Senzaki H. The pathophysiology of coronary artery aneurysms in Kawasaki disease: role of matrix metalloproteinases. Arch Dis Child. 2006;91:847-851.

• 全文
• 摘要

20.  Arnson Y, Shoenfeld Y, Amital H. Intravenous immunoglobulin therapy for autoimmune diseases. Autoimmunity. 2009;42:553-560.

• 摘要

21.  Suzuki A, Miyagawa-Tomita S, Komatsu K, et al. Immunohistochemical study of apparently intact coronary artery in a child after Kawasaki disease. Pediatr Int. 2004;46:590-596.

• 摘要

22.  Onouchi Y, Tamari M, Takahashi A, et al. A genomewide linkage analysis of Kawasaki disease: evidence for linkage to chromosome 12. J Hum Genet. 2007;52:179-190.

• 摘要

23.  Satou GM, Giamelli J, Gewitz MH. Kawasaki disease: diagnosis, management, and long-term implications. Cardiol Rev. 2007;15:163-169.

• 摘要

24.  Kawasaki T, Kosaki T, Okawa S, et al. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics. 1974;54:271-276.

• 摘要

25.  Saguil A, Fargo M, Grogan S. Diagnosis and management of Kawasaki disease. Am Fam Physician. 2015;91:365-371.

• 全文
• 摘要

26.  Smith MT, Lester-Smith D, Zurynski Y, et al. Persistence of acute rheumatic fever in a tertiary children's hospital. J Paediatr Child Health. 2011;47:198-203.

• 摘要

27.  Oates-Whitehead RM, Baumer JH, Haines L, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2003;(4):CD004000.

• 全文
• 摘要

28.  Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324:1633-1639.

• 摘要

29.  Sundel RP, Burns JC, Baker A, et al. Gamma globulin re-treatment in Kawasaki disease. J Pediatr. 1993;123:657-659.

• 摘要

30.  Han RK, Sinclair B, Newman A, et al. Recognition and management of Kawasaki disease. CMAJ. 2000;162:807-812.

• 全文
• 摘要

31.  Wright DA, Newburger JW, Baker A, et al. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr. 1996;128:146-149.

• 摘要

32.  Kijima Y, Kamiya T, Suzuki A, et al. A trial procedure to prevent aneurysm formation of the coronary artery by steroid pulse therapy in Kawasaki disease. Jpn Circ J. 1982;46:1239-1242.

• 摘要

33.  Inoue Y, Okada Y, Shinohara M, et al. Multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome. J Pediatr. 2006;149:336-341.

• 摘要

34.  Newberger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 2007;356:663-675.

• 全文
• 摘要

35.  Newburger JW. Kawasaki disease: medical therapies. Congenit Heart Dis. 2017 Jun 5 [Epub ahead of print].

• 摘要

36.  Wardle AJ, Connolly GM, Seager MJ, et al. Corticosteroids for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2017;(1):CD011188.

• 全文
• 摘要

37.  Petty RE, Cassidy JT. Kawasaki disease. In: Cassidy JT, Petty RE, eds. Textbook of pediatric rheumatology. 4th ed. Philadelphia, PA: W.B. Saunders; 2001:580-594.

38.  Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005;146:662-667.

• 摘要

39.  Son MB, Gauvreau K, Ma L, et al. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics. 2009;124:1-8.

• 摘要

40.  Tremoulet AH, Jain S, Jaggi P, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet. 2014;383:1731-1738.

• 摘要

41.  Sonoda K, Mori M, Hokosaki T, et al. Infliximab plus plasma exchange rescue therapy in Kawasaki disease. J Pediatr. 2014;164:1128-1132.

• 摘要

42.  Chen S, Dong Y, Yin Y, et al. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis. Heart. 2013;99:76-82.

• 摘要

43.  Zhu BH, Lv HT, Sun L, et al. A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease. Eur J Pediatr. 2012;171:571-578.

• 全文
• 摘要

44.  Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012;379:1613-1620.

• 摘要

45.  Son MB, Newburger JW. Management of Kawasaki disease: corticosteroids revisited. Lancet. 2012;379:1571-1572.

• 摘要

46.  Curtis N. Prednisolone added to intravenous immunoglobulin treatment improves outcome in children with severe Kawasaki disease. Arch Dis Child Educ Pract Ed. 2013;98:77-78.

• 摘要

47.  Beiser AS, Takahasha M, Baker AL, et al. A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. Am J Cardiol. 1998;81:1116-1120.

• 摘要

48.  Mori M, Imagawa T, Yasui K, et al. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. J Pediatr. 2000;137:177-180.

• 摘要

49.  Fukunishi M, Kikkawa M, Hamana K, et al. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. J Pediatr. 2000;137:172-176.

• 摘要

50.  Nakamura Y, Yashiro M, Uehara R, et al. Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease. Pediatr Int. 2004;46:33-38.

• 摘要

51.  Marquez J, Gedalia O, Candia L, et al. Kawasaki disease: clinical spectrum of 88 patients in a high-prevalence African-American population. J Natl Med Assoc. 2008;100:28-32.

• 摘要

52.  Gersony WM. The adult after Kawasaki disease: the risks for late coronary events. J Am Coll Cardiol. 2009;54:1921-1923.

• 全文
• 摘要

53.  Friedman KG, Gauvreau K, Hamaoka-Okamoto A, et al. Coronary artery aneurysm in Kawasaki disease: risk factors for progressive disease and adverse cardiac events in US population. J Am Heart Assoc. 2016;5:e003289.

• 全文
• 摘要

54.  Rowley AH, Shulman ST. Kawasaki disease. In: Kliegman RM, Marcdante K, Behrman RE, et al, eds. Nelson textbook of pediatrics. 18th ed. Philadelphia, PA: Saunders Elsevier; 2004:1036-1042.